Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Phase 1 Study of Autologous Dendritic Cell Immunotherapy in Patients With mCRPC

15. september 2026 oppdatert av: Pharmicell Co., Ltd.

En åpen etikett, enkeltsenter, fase 1-studie for å evaluere sikkerheten ved kreftimmunterapi med autologe dendrittiske celler hos pasienter med metastatisk kastrasjonsresistent prostatakreft (mCRPC)

The goal of this clinical trial was to evaluate the safety of Cellgram-DC-PC, an autologous dendritic cell-based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Studieoversikt

Status

Avsluttet

Intervensjon / Behandling

Detaljert beskrivelse

Cellgram-DC-PC is an autologous dendritic cell-based cancer immunotherapy developed for patients with metastatic castration-resistant prostate cancer (mCRPC). This was a Phase 1, single-center, open-label clinical trial designed to characterize the safety profile of Cellgram-DC-PC following administration in patients with mCRPC.

Studietype

Intervensjonell

Registrering (Faktiske)

3

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

19 år til 79 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Mann

Beskrivelse

Inclusion Criteria:

  1. 19 and under 80 years

  2. Histologically confirmed prostate adenocarcinoma

  3. Patients with stage M1a or M1b with extrapelvic lymph nodes and bone metastases

  4. Patients diagnosed with castration-resistant prostate cancer after failure of male hormone deprivation therapy (Castrate levels of testosterone <50 ng/dL) and If either a or b is satisfied:

    1. Biochemical progression: Prostate Specific Antigen (PSA) increases three times in a row at 1 week intervals, two 50% increases compared to the lowest point, PSA> 2ng/mL, or
    2. Radiological progression: appearance of new lesions; 2 or more new lesions on the bone scan
  5. Asymptomatic or mild patients after previous treatment

    1. Patients who have not used narcotic analgesics within 21 days prior to enrollment
    2. Patients with an average weekly pain of less than 4 on the Visual Analogue Scale(VAS) (out of 10)
  6. Combination of Luteinizing hormone-releasing hormone(LHRH) analogs (leuprolide (Lupron, Viadur, Eligard) and goserelin (Zoladex, etc.) for the inhibition of gonadotropin is allowed

  7. Whole body performance status: European Cooperative Oncology Group(ECOG) 0~1

  8. Patients whose life expectancy is at least 6 months or longer

  9. Hb ≥ 8.0g/dL, Absolute Neutrophil Count(ANC) ≥ 1,500/mm3, Platelets ≥ 100,000/mm3

  10. Serum Creatinine ≤ 2.0 x Upper Limit of Normal(ULN) or Calculated Creatinine Clearance > 30mL/min

  11. Total Bilirubin ≤ 1.5 x ULN or Direct bilirubin ≤ ULN, Aminotransferase (AST)/Alanine aminotransferase(ALT) <2.5 x ULN

  12. Patients who did not receive surgery, radiation therapy, or immunotherapy within the last 6 weeks and recovered from side effects

  13. Patients who agreed to use medically recognized contraceptive methods during the clinical trial participation period

  14. Patients who voluntarily participated in clinical trials and signed the Informed Contents Form (ICF)

Exclusion Criteria:

  1. Patients who have a local recurrence and are scheduled for local treatment.
  2. Patients with malignant tumors other than non-melanoma skin cancer in the past 3 years
  3. Patients with visceral metastases (metastases to the lungs, liver, adrenal glands, peritoneum, brain, etc.)
  4. Patients who previously received anti-tumor immunotherapy (anti-PD1, anti-PDL1 or anti-PDL2, etc.) or participated in immunotherapy-related clinical trials
  5. Patients with active autoimmune diseases requiring systemic immunosuppression treatment (e.g., immunosuppressants such as cyclosporin A or azathioprine or steroids for disease control)
  6. Patients with medical conditions requiring continuous or intermittent administration of systemic steroids or immunosuppressants
  7. Patients who received blood products (limited to whole blood products) within 4 weeks of screening criteria, or patients who received colony stimulating factors (Colony Stimulating Factor or recombinant Erythropoietin)
  8. Patients with a history of organ or hematopoietic stem cell transplantation
  9. Patients with acute or chronic infections requiring systemic treatment
  10. Patients known to be infected with human immunodeficiency virus (HIV)/serum positive
  11. Patients with active hepatitis A, B or C
  12. Patients with untreated syphilis (Fluorescent Treponemal Antibody Absorption Test (FTA-ABS) Immunoglobulin M positive patients)
  13. Patients expected to require therapeutic biotherapy or immunotherapy
  14. Patients who received live virus vaccines (e.g. measles, mumps, rubella, chickenpox, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), oral typhoid vaccine, Flu-Mist, etc.) within 30 days
  15. Patients with a history of anaphylaxis to gentamicin
  16. Others, if the person in charge of the study determines that it is not suitable for the clinical trial

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Cellgram-DC-PC

Participants received Cellgram-DC-PC by subcutaneous injection near the inguinal lymph nodes.

Patients received three subcutaneous injections of Cellgram-DC-PC (autologous dendritic cells) near the inguinal lymph nodes at Weeks 0, 2, and 4.

Andre navn:
  • Autolog dendritisk celle anti-kreft immuncelleterapi for behandling av prostatakreft

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Adverse Event
Tidsramme: From informed consent to the end of treatment at Week 28.

Adverse events (AEs) were assessed for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

From informed consent to the end of treatment at Week 28.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Immune Response
Tidsramme: At baseline (Week 0), Week 4, Week 8, Week 16, and Week 28.

Tumor antigen-specific immune responses were evaluated by measuring changes in serum IFN-γ and IL-12 levels and antigen-specific T-cell responses following administration of the investigational product.

At baseline (Week 0), Week 4, Week 8, Week 16, and Week 28.
Change in Prostate-Specific Antigen (PSA)
Tidsramme: At baseline (Week 0), Week 2, Week 4, Week 8, Week 16, and Week 28.

Exploratory efficacy was evaluated by measuring changes in prostate-specific antigen (PSA) levels from pre-treatment (Week 0) to post-treatment assessment.

At baseline (Week 0), Week 2, Week 4, Week 8, Week 16, and Week 28.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: BUMJIN LIM, Ph.D, Asan Medical Center

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

5. juli 2021

Primær fullføring (Faktiske)

15. februar 2022

Studiet fullført (Faktiske)

30. juni 2022

Datoer for studieregistrering

Først innsendt

22. oktober 2020

Først innsendt som oppfylte QC-kriteriene

2. november 2020

Først lagt ut (Faktiske)

4. november 2020

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

21. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Individual participant data will not be made available to other researchers.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere